Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma

  • Paik, Eun Kyung (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Kim, Mi-Sook (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Choi, Chul Won (Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences) ;
  • Jang, Won Il (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Lee, Sung Hyun (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Choi, Sang Hyoun (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Kim, Kum Bae (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Lee, Dong Han (CyberKnife Center, Korea Institute of Radiological and Medical Sciences)
  • Received : 2015.04.07
  • Accepted : 2015.09.03
  • Published : 2015.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To compare volumetric modulated arc therapy of RapidArc with robotic stereotactic body radiation therapy (SBRT) of CyberKnife in the planning and delivery of SBRT for hepatocellular carcinoma (HCC) treatment by analyzing dosimetric parameters. Materials and Methods: Two radiation treatment plans were generated for 29 HCC patients, one using Eclipse for the RapidArc plan and the other using Multiplan for the CyberKnife plan. The prescription dose was 60 Gy in 3 fractions. The dosimetric parameters of planning target volume (PTV) coverage and normal tissue sparing in the RapidArc and the CyberKnife plans were analyzed. Results: The conformity index was $1.05{\pm}0.02$ for the CyberKnife plan, and $1.13{\pm}0.10$ for the RapidArc plan. The homogeneity index was $1.23{\pm}0.01$ for the CyberKnife plan, and $1.10{\pm}0.03$ for the RapidArc plan. For the normal liver, there were significant differences between the two plans in the low-dose regions of $V_1$ and $V_3$. The normalized volumes of $V_{60}$ for the normal liver in the RapidArc plan were drastically increased when the mean dose of the PTVs in RapidArc plan is equivalent to the mean dose of the PTVs in the CyberKnife plan. Conclusion: CyberKnife plans show greater dose conformity, especially in small-sized tumors, while RapidArc plans show good dosimetric distribution of low dose sparing in the normal liver and body.

Keywords

References

  1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-S16. https://doi.org/10.1053/j.gastro.2004.09.011
  2. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54. https://doi.org/10.1148/radiol.2241011262
  3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  4. Shiina S, Tateishi R, Imamura M, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int 2012;32:1434-42. https://doi.org/10.1111/j.1478-3231.2012.02838.x
  5. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 2005;103:1201-9. https://doi.org/10.1002/cncr.20892
  6. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 2011;7:463-75. https://doi.org/10.4103/0973-1482.92023
  7. Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 2011;21:271-7. https://doi.org/10.1016/j.semradonc.2011.05.002
  8. Kim SH, Kang MK, Yea JW, Kim SK, Choi JH, Oh SA. The impact of beam angle configuration of intensity-modulated radiotherapy in the hepatocellular carcinoma. Radiat Oncol J 2012;30:146-51. https://doi.org/10.3857/roj.2012.30.3.146
  9. Kim YI, Park HC, Lim do H, et al. Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J 2012;30:189-96. https://doi.org/10.3857/roj.2012.30.4.189
  10. Seo YS, Kim MS, Yoo SY, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010;102:209-14. https://doi.org/10.1002/jso.21593
  11. Shin YJ, Kim MS, Yoo SY, et al. Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies. Tumori 2010;96:65-70. https://doi.org/10.1177/030089161009600111
  12. Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-31. https://doi.org/10.1002/cncr.27533
  13. Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-50. https://doi.org/10.1016/j.ijrobp.2004.08.028
  14. Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992;23:781-8. https://doi.org/10.1016/0360-3016(92)90651-W
  15. Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002;54:156-62.
  16. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62:1371-8. https://doi.org/10.1016/j.ijrobp.2005.01.002
  17. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 2008;18:215-22. https://doi.org/10.1016/j.semradonc.2008.04.001
  18. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010;37:4078-101. https://doi.org/10.1118/1.3438081
  19. Macdougall ND, Dean C, Muirhead R. Stereotactic body radiotherapy in prostate cancer: is rapidarc a better solution than cyberknife? Clin Oncol (R Coll Radiol) 2014;26:4-9. https://doi.org/10.1016/j.clon.2013.08.008
  20. Wu VW, Tam KW, Tong SM. Evaluation of the influence of tumor location and size on the difference of dose calculation between Ray Tracing algorithm and Fast Monte Carlo algorithm in stereotactic body radiotherapy of non-small cell lung cancer using CyberKnife. J Appl Clin Med Phys 2013;14:68-78. https://doi.org/10.1120/jacmp.v14i5.4280
  21. Palma D, Vollans E, James K, et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:996-1001. https://doi.org/10.1016/j.ijrobp.2008.02.047
  22. Dutta D, Balaji Subramanian S, Murli V, Sudahar H, Gopalakrishna Kurup PG, Potharaju M. Dosimetric comparison of Linac-based (BrainLAB$^{(R)}$) and robotic radiosurgery (CyberKnife$^{(R)}$) stereotactic system plans for acoustic schwannoma. J Neurooncol 2012;106:637-42. https://doi.org/10.1007/s11060-011-0703-5
  23. Atalar B, Aydin G, Gungor G, Caglar H, Yapici B, Ozyar E. Dosimetric comparison of robotic and conventional linac-based stereotactic lung irradiation in early-stage lung cancer. Technol Cancer Res Treat 2012;11:249-55. https://doi.org/10.7785/tcrt.2012.500293
  24. Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013;8:250. https://doi.org/10.1186/1748-717X-8-250
  25. Lin YW, Lin KH, Ho HW, et al. Treatment plan comparison between stereotactic body radiation therapy techniques for prostate cancer: non-isocentric CyberKnife versus isocentric RapidArc. Phys Med 2014;30:654-61. https://doi.org/10.1016/j.ejmp.2014.03.008
  26. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys 2006;64:333-42. https://doi.org/10.1016/j.ijrobp.2005.09.028
  27. Cochrane AM, Murray-Lyon IM, Brinkley DM, Williams R. Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 1977;40:609-14. https://doi.org/10.1002/1097-0142(197708)40:2<609::AID-CNCR2820400203>3.0.CO;2-L
  28. Stillwagon GB, Order SE, Guse C, et al. Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01. Int J Radiat Oncol Biol Phys 1991;20:65-71. https://doi.org/10.1016/0360-3016(91)90139-U
  29. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007;2:21. https://doi.org/10.1186/1748-717X-2-21
  30. Shueng PW, Lin SC, Chang HT, et al. Toxicity risk of non-target organs at risk receiving low-dose radiation: case report. Radiat Oncol 2009;4:71. https://doi.org/10.1186/1748-717X-4-71

Cited by

  1. Effectiveness of the Monte Carlo method in stereotactic radiation therapy applied to quasi-homogenous brain tumors vol.7, pp.11, 2015, https://doi.org/10.18632/oncotarget.7280
  2. Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis vol.9, pp.None, 2015, https://doi.org/10.2147/ott.s100040
  3. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis vol.22, pp.30, 2016, https://doi.org/10.3748/wjg.v22.i30.6851
  4. Gated Volumetric-Modulated Arc Therapy vs. Tumor-Tracking CyberKnife Radiotherapy as Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Dosimetric Comparison Study Focused on the Impact of vol.11, pp.11, 2015, https://doi.org/10.1371/journal.pone.0166927
  5. Gastroenteropancreatic—origin neuroendocrine carcinomas : Three case reports with favorable responses following localized radiotherapy and a review of literature vol.96, pp.49, 2015, https://doi.org/10.1097/md.0000000000009009
  6. Correlation analysis between 2D and quasi-3D gamma evaluations for both intensity-modulated radiation therapy and volumetric modulated arc therapy vol.8, pp.3, 2015, https://doi.org/10.18632/oncotarget.12279
  7. Dosimetric effects of sectional adjustments of collimator angles on volumetric modulated arc therapy for irregularly-shaped targets vol.12, pp.4, 2015, https://doi.org/10.1371/journal.pone.0174924
  8. The dosimetric impact of the prescription isodose line (IDL) on the quality of robotic stereotactic radiosurgery (SRS) plans vol.44, pp.12, 2017, https://doi.org/10.1002/mp.12630
  9. Nearest Neighbor Method to Estimate Internal Target for Real-Time Tumor Tracking vol.17, pp.None, 2015, https://doi.org/10.1177/1533033818786597
  10. Optimal collimator rotation based on the outline of multiple brain targets in VMAT vol.13, pp.None, 2015, https://doi.org/10.1186/s13014-018-1039-5
  11. In silico assessment of the dosimetric quality of a novel, automated radiation treatment planning strategy for linac-based radiosurgery of multiple brain metastases and a comparison with robotic metho vol.13, pp.1, 2015, https://doi.org/10.1186/s13014-018-0997-y
  12. Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity‐matched analysis of Surveillance, Epidemiology, and End Results database vol.8, pp.2, 2015, https://doi.org/10.1002/cam4.1937
  13. Transarterial Chemoembolization with LC Bead LUMI followed by Stereotactic Body Radiation Therapy in Treatment of Hepatocellular Carcinoma vol.7, pp.1, 2015, https://doi.org/10.1016/j.adro.2021.100830